Corneal toxicity of cell-penetrating peptides that inhibit Herpes simplex virus entry

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 4, 2006, Pages 279-289

  Akkarawongsa, Radeekorn ^a   Cullinan, Amy E ^a   Zinkel, Andrew ^a   Clarin, Joshua ^a   Brandt, Curtis R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b 6630 Medical Sciences Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BHOMD PEPTIDE; BHOMFF PEPTIDE; BKLA PEPTIDE; CELL PENETRATING PEPTIDE; EB PEPTIDE; EBX PEPTIDE; FORMAZAN; PENETRATIN; PEPTIDE; TAT C PEPTIDE; UNCLASSIFIED DRUG; CARRIER PROTEIN; FGF4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 4; PEPTIDE FRAGMENT; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CORNEA CELL; DRUG CYTOTOXICITY; EYE TOXICITY; FEMALE; HELA CELL; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROPHYLAXIS; SKIN FIBROBLAST; TRABECULAR MESHWORK; VERO CELL; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CERCOPITHECUS; CORNEA; DRUG EFFECT; FIBROBLAST; HERPES SIMPLEX VIRUS 1; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CORNEA; FEMALE; FIBROBLAST GROWTH FACTOR 4; FIBROBLASTS; GENE PRODUCTS, TAT; HELA CELLS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; TRABECULAR MESHWORK; VERO CELLS;

EID: 33749155631     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.279     Document Type: Article

References (42)

1. Whitley, RJ. Herpes simplex viruses. In: Fields, B.N., Knipe, D.M., Howley, P.M., eds. Fields Virology, Vol. 2. Philadelphia, PA: Lippencott-Raven, 1996:2297-2342.
2. Liesegang, T.J. Herpes simplex virus epidemiology and ocular importance. Cornea 20:1-13, 2001.
3. Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease. Arch. Ophthalmol. 118:1030-1036, 2000.
4. Wilhelmus, K.R., Gee, L., Hauck, W.W., et al. Herpetic eye disease study: A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 101:1883-1895, 1994.
5. Shimeld, C., Tullo, A.B., Easty, D.L., et al. Isolation of herpes simplex virus from the cornea in chronic stromal keratitis. Br. J. Ophthalmol. 66:643-647, 1982.
6. Kaye, S.B., Lynas, C., Patterson, A., et al. Evidence for herpes simplex virus latency in the human cornea. Br. J. Ophthalmol. 75:195-200, 1991
7. Openshaw, H., McNeill, J.I., Lin, X.H., et al. Herpes simplex virus DNA in normal corneas: Persistence without viral shedding from the ganglion. J. Med. Virol. 46:75-80, 1995.
8. O'Brien, W.J., Tsao, L.S., and Taylor, J.L. Tissue-specific accumulation of latency-associated transcripts in herpes virus-infected rabbits. Invest. Ophthalmol. Vis. Sci. 39:1847-1853, 1998.
9. Cleator, G.M., Klapper, P.E., Dennett, C., et al. Corneal donor infection by herpes simplex virus: Herpes simplex virus DNA in donor corneas. Cornea 13:294-304, 1994.
10. Morris, D.J., Cleator, G.M., Klapper, P.E., et al. Detection of herpes simplex virus DNA in donor cornea culture medium by polymerase chain reaction. Br. J. Ophthalmol. 80:654-657, 1996.
11. Brandt, C.R., Coakley, L.M., and Grau, D.R. A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. J. Virol. Meth. 36:209-222, 1992.
12. Brandt, C.R., Spencer, B., Imesch, P., et al. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob. Agents Chemother. 40:1078-1084, 1996.
13. Lindgren, M., Hallbrink M., Prochiantz, A., et al. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:99-103, 2000.
14. Lindsay, M.A. Peptide-mediated cell delivery: Application in protein target validation. Curr. Opin. Pharmacol. 2:587-594, 2002.
15. Gariepy, J., and Kawamura, K. Vectorial delivery of macromolecules into cells using peptide-based vehicles. Trends Biotech. 19:21-28, 2001.
16. Vives, E. Present and future of cell-penetrating peptide-mediated delivery systems: Is the Trojan Horse too wild to go only to Troy? J. Contr. Rel. 109:77-85, 2005.
17. Dietz, G.P., and Bahr, M. Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res. Bull 68:103-114, 2005.
18. Snyder, E.L., and Dowdy, S.F. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins, and nucleic acids in vivo. Exp. Opin. Drug Deliv. 2:43-51, 2005.
19. Deshayes, S., Morris, M.C., Divita, G., et al. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol. Life Sci. 62:1839-1849, 2005.
20. Wadia, J.S., and Dowdy, S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Res. 57:579-596, 2005.
21. Bultmann, H., Busse, J.S., and Brandt, C.R. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75:2634-2645, 2001.
22. Bultmann, H., and Brandt, C.R. Peptides containing membrane-transiting motifs inhibit virus entry. J. Biol. Chem. 277:36018-36023, 2002.
23. Merrifield, R.B. Solid-phase peptide synthesis I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:7129-7133, 1963.
24. Meienhofer, J., Waki, M., Heimer, E.P., et al. Solid-phase synthesis without repetitive acidolysis. J. Peptide Prot. Res. 13:35-42, 1979.
25. Fields, G.G., Lloyd, D.H., MacDonald, R.L., et al. HBTU activation for automated fmoc solid-phase peptide synthesis. Peptide Res. 4:95-101, 1991
26. Segal, LH. Biochemical Calculations. New York, NY: John Wiley & Sons, 1976.
27. Peters, D.M, Dowd, N., Brandt, C.R., et al. Human papilloma virus E6/E7 genes can expand the lifespan of human corneal fibroblasts. In vitro Cell. Dev. Biol.-Animal 32:279-284, 1996.
28. Liu, X., Huang, C.-Y., Cai, S., et al. Transformation of human trabecular meshwork cells with SV40 Tag alters promoter utilization. Curr. Eye Res. 25:347-353, 2002.
29. Fotin-Mleczek, M., Welte, S., Mader, O., et al. Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J. Cell Sci. 118:3339-3351, 2005.
30. Hallbrink, M., Floren, A., Elmquist, A., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochem. Biophys. Acta. 1515:101-109, 2001.
31. Sarr, K., Lindgren, M., Hansen, M., et al. Cell-penetrating peptides: A comparative membrane toxicity study. Anal. Biochem. 345:55-65, 2005.
32. Trehin, R., Krauss, U., Muff, R., et al. Cellular internalization of human calcitonin-derived peptides in MDCK monolayers: A comparative study with TAT (47-57) and penetratin (43-58). Pharm. Res. 21:33-42, 2004.
33. Jones, S.W., Christison, R., Bundell, K., et al. Characterization of cell-penetrating, peptide-mediated delivery. Br. J. Pharmacol. 145:1093-1102, 2005.
34. Koppelhus, U., Awasthi, S.K., Zachar, V., et al. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nuc. Acid Drug Dev. 12:51-63, 2002.
35. Harbour, J.W., Worley, L., Duanduan, M., et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 120:1341-1346, 2002.
36. Srinivas, R.V., Birkedal, B., Owens, R.J., et al. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 176:48-57, 1990.
37. Lambert, D.M., Barney, S., Lambert, A., et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. U.S.A. 93:2186-2191, 1996.
38. Chan, D.C., and Kim, P.S. HIV entry and its inhibition. Cell 98:681-684, 1998.
39. Eckert, D.M., and Kim, P.S. Design of potent inhibitors of HIV-1 entry from the gp41 n-peptide region. Proc. Natl. Acad. Sci. U.S.A. 98:11187-11192, 2001.
40. Samuel, O., and Shai, Y. Participation of two fusion peptides in measles virus-induced membrane fusion: Emerging similarity with other paramyxoviruses. Biochemistry 40:1340-1349, 2001.
41. Gosh, J.K., Peisajovich, S.G., and Shai, Y. Sendai virus internal fusion peptide: Structural and functional characterization as a plausible mode of viral entry inhibition. Biochemistry 39:11581-11592, 2000.
42. Judice, J.K., Tom, J.Y.K., Huang, W., et al. Inhibition of HIV type-1 infectivity by constrained α-helical peptides: Implications for the viral fusion mechanism. Proc. Natl. Acad. Sci. U.S.A. 94:1426-1430,1997.